Monday, August 10, 2020

Ligand Acquires Pfenex

San Diego-based Ligand Pharmaceuticals anounced on Monday that it has acquired Pfenex, a develope rof recombinant protein production technology. According to Ligand, it will pay $12.00 per share in cash, or $438M in equity value, plus an additional $2.00 a share and $78M in milestones for Pfenex. The deal is wort

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.